ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.4745del (p.Asp1582fs)

dbSNP: rs80357907
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000112393 SCV000300157 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Department of Medical Genetics, Oslo University Hospital RCV000112393 SCV000564331 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2015-07-01 criteria provided, single submitter clinical testing
Invitae RCV000496283 SCV001584608 pathogenic Hereditary breast ovarian cancer syndrome 2022-08-11 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 55278). This variant is also known as 4864delA. This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 17574839). This variant is present in population databases (rs80357907, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Asp1582Alafs*19) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584).
Ambry Genetics RCV003338399 SCV004058422 pathogenic Hereditary cancer-predisposing syndrome 2023-07-12 criteria provided, single submitter clinical testing The c.4745delA pathogenic mutation, located in coding exon 14 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 4745, causing a translational frameshift with a predicted alternate stop codon (p.D1582Afs*19). In one study, this alteration was observed in 42 individuals from 6 Norwegian families undergoing testing given a personal and/or family history of HBOC-related cancers (Møller P et al. Eur J Cancer, 2007 Jul;43:1713-7). Of note, this alteration is also designated as 4864delA in the published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Breast Cancer Information Core (BIC) (BRCA1) RCV000112393 SCV000145171 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 1999-06-21 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto RCV000496283 SCV000587426 pathogenic Hereditary breast ovarian cancer syndrome 2014-01-31 no assertion criteria provided research
BRCAlab, Lund University RCV000112393 SCV002588817 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2022-08-26 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.